Biotech rNPV approach question

Hey guys. I am doing a valuation of a young growth biotech firm. My method is the risk adjusted probability based NPV in which I analyze the pipeline and potential marketable products to ascertain a firm value. So far I have had no problem in individually analyzing the products and estimating future product revenue. However, I am now struggling to incorporate collaborative R&D revenue, the non dilutive financing often used by young biotech firms, and grant revenue. I do not have access to the precise nature of the agreements and licensing deals so am unsure how to predict the trend of this revenue accumulation. My solution is to get the values and evenly spread them out over the life of the product as it reaches milestones and collects the revenue. However, the time value of money may under or over value this portion of the revenue as in reality it may be recognized earlier or later. This will have a significant impact on firm value since it is a growth firm which is not making product based revenue until 2018. Furthermore, the product based revenues are probability adjusted based on the phase of clinical trials they are in and the nature of the disease/need they are trying to treat. Hence, for the next 4 years, the main driver of value is the milestone revenue, and payments made for the covering of R&D costs. Are there any established professionals in healthcare banking who could shed any light on how to tackle this issue in a less crude manner? Or anyone with some innovative ideas? Thanks for the help.

1 Comments
 

Iusto enim rerum doloremque expedita vitae veniam. Doloribus quaerat amet necessitatibus.

Voluptate in numquam reprehenderit incidunt temporibus. Aut voluptatem voluptates alias vel. Qui dicta eum ex quos iusto iusto ut.

Odio nisi et nulla perferendis. Magni temporibus adipisci perspiciatis eveniet autem tempora ea.

Labore delectus at veritatis et quas maiores numquam doloremque. Libero consequatur et perspiciatis perspiciatis corrupti id officia. Doloribus dolor dolorem cumque ea et qui. Sunt qui earum dolorum officiis qui doloremque est. Qui distinctio quod officiis sunt. Aut assumenda tempora a omnis.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
GameTheory's picture
GameTheory
98.9
7
DrApeman's picture
DrApeman
98.9
8
dosk17's picture
dosk17
98.9
9
CompBanker's picture
CompBanker
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”